B-type natriuretic peptide: Issues for the intensivist and pulmonologist

Critical Care Medicine

Volumn 33, Issue 9, 2005, Pages 2094-2013

  Jason, Phua ^a   Keang, Lim Tow ^a   Hoe, Lee Kang ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

B type natriuretic peptide; Critical illness; Heart failure; N terminal pro B type natriuretic peptide; Pulmonary diseases

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; PROTEIN PRECURSOR;

AMINO TERMINAL SEQUENCE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CRITICAL ILLNESS; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE SEVERITY; HEART DISEASE; HEART FAILURE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTENSIVE CARE; KIDNEY FAILURE; LUNG DISEASE; LUNG EMBOLISM; NATRIURESIS; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; PULMONOLOGY; RESPIRATORY DISTRESS; REVIEW; SHOCK;

EID: 24944448840     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000178351.03327.9F     Document Type: Review

References (146)

1. de Lemos JA, McGuire DK, Drazner MH: B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362:316-322
2. Silver MA, Maisel A, Yancy CW, et al: BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail 2004; 10(5 Suppl 3):S1-S30
3. Sudoh T, Kangawa K, Minamino N, et al: A new natriuretic peptide in porcine brain. Nature 1988; 332:78-81
4. Hosoda K, Nakao K, Mukoyama M, et al: Expression of brain natriuretic peptide gene in human heart. Production in the ventricle. Hypertension 1991; 17:1152-1155
5. Sawada Y, Suda M, Yokoyama H, et al: Stretch-induced hypertrophic growth of cardiocytes and processing of brain-type natriuretic peptide are controlled by proprotein-processing endoprotease furin. J Biol Chem 1997; 272:20545-20554
6. Wiese S, Breyer T, Dragu A, et al: Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: Influence of angiotensin II and diastolic fiber length. Circulation 2000; 102:3074-3079
7. Nakagawa O, Ogawa Y, Itoh H, et al: Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J Clin Invest 1995; 96:1280-1287
8. Suga S, Nakao K, Hosoda K, et al: Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology 1992; 130:229-239
9. Zhou HL, Fiscus RR: Brain natriuretic peptide (BNP) causes endothelium-independent relaxation and elevation of cyclic GMP in rat thoracic aorta. Neuropeptides 1989; 14:161-169
10. Marcus LS, Hart D, Packer M, et al: Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 1996; 94:3184-3189
11. Holmes SJ, Espiner EA, Richards AM, et al: Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab 1993; 76:91-96
12. Magga J, Puhakka M, Hietakorpi S, et al: Atrial natriuretic peptide, B-type natriuretic peptide, and serum collagen markers after acute myocardial infarction. J Appl Physiol 2004; 96:1306-1311
13. Brunner-La Rocca HP, Kaye DM, Woods RL, et al: Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol 2001; 37:1221-1227
14. Mukoyama M, Nakao K, Hosoda K, et al: Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87:1402-1412
15. Smith MW, Espiner EA, Yandle TG, et al: Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase. J Endocrinol 2000; 167:239-246
16. McCullough PA, Ornland T, Maisel AS: B-type natriuretic peptides: A diagnostic breakthrough for clinicians. Rev Cardiovasc Med 2003; 4:72-80
17. Clerico A, Emdin M: Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: A review. Clin Chem 2004; 50:33-50
18. Hammerer-Lercher A, Ludwig W, Falkensammer G, et al: Natriuretic peptides as markers of mild forms of left ventricular dysfunction: Effects of assays on diagnostic performance of markers. Clin Chem 2004; 50:1174-1183
19. Seino Y, Ogawa A, Yamashita T, et al: Application of NT-proBNP and BNP measurements in cardiac care: A more discerning marker for the detection and evaluation of heart failure. Eur J Heart Fail 2004; 6:295-300
20. Lainchbury JG, Campbell E, Frampton CM, et al: Brain natriuretic peptide and N- terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 2003; 42:728-735
21. Davis M, Espiner E, Richards G, et al: Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 1994; 343:440-444
22. Dao Q, Krishnaswamy P, Kazanegra R, et al: Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001; 37:379-385
23. Morrison LK, Harrison A, Krishnaswamy P, et al: Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002; 39:202-209
24. Maisel AS, Krishnaswamy P, Nowak RM, et al: Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347:161-167
25. Logeart D, Saudubray C, Beyne P, et al: Comparative value of Doppler echocardiography and B-type natriuretic peptide assay in the etiologic diagnosis of acute dyspnea. J Am Coll Cardiol 2002; 40:1794-1800
26. Villacorta H, Duarte A, Duarte NM, et al: The role of B-type natriuretic peptide in the diagnosis of congestive heart failure in patients presenting to an emergency department with dyspnea. Ar Qbras Cardiol 2002; 79:569-572
27. Knudsen CW, Riis JS, Finsen AV, et al: Diagnostic value of a rapid test for B-type natriuretic peptide in patients presenting with acute dyspnoea: effect of age and gender. Eur J Heart Fail 2004; 6:55-62
28. McCullough PA, Nowak RM, McCord J, et al: B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: Analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002; 106:416-422
29. Doust JA, Glasziou PP, Pietrzak E, et al: A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Mem Med 2004; 164:1978-1984
30. Mueller C, Scholer A, Laule-Kilian K, et al: Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004; 350:647-654
31. Mueller C, Laule-Kilian K, Scholer A, et al: Use of B-type natriuretic peptide for the management of women with dyspnea. Am J Cardiol 2004; 94:1510-1514
32. Bayes-Genis A, Santalo-Bel M, Zapico-Muniz E, et al: N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur J Heart Fail 2004; 6:301-308
33. Bruins S, Fokkema MR, Romer JW, et al: High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 2004; 50:2052-2058
34. Tsutamoto T, Wada A, Maeda K, et al: Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96:509-516
35. Koglin J, Pehlivanli S, Schwaiblmair M, et al: Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001; 38:1934-1941
36. Berendes E, Van Aken H, Raufhake C, et al: Differential secretion of atrial and brain natriuretic peptide in critically ill patients. Anesth Analg 2001; 93:676-682
37. McLean AS, Tang B, Nalos M, et al: Increased B-type natriuretic peptide (BNP) level is a strong predictor for cardiac dysfunction in intensive care unit patients. Anaesth Intensive Care 2003; 31:21-27
38. McLean AS, Huang SJ, Nalos M, et al: The confounding effects of age, gender, serum creatinine, and electrolyte concentrations on plasma B-type natriuretic peptide concentrations in critically ill patients. Crit Care Med 2003; 31:2611-2618
39. Tung RH, Garcia C, Morss AM, et al: Utility of B-type natriuretic peptide for the evaluation of intensive care unit shock. Crit Care Med 2004; 32:1643-1647
40. Witthaut R, Busch C, Fraunberger P, et al: Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: Impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med 2003; 29:1696-1702
41. Cuthbertson BH, Patel RR, Croal BL, et al: B-type natriuretic peptide and the prediction of outcome in patients admitted to intensive care. Anaesthesia 2005; 60:16-21
42. Charpentier J, Luyt CE, Fulla Y, et al: Brain natriuretic peptide: A marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med 2004; 32:660-665
43. Chua G, Kang-Hoe L: Marked elevations in N-terminal brain natriuretic peptide levels in septic shock. Crit Care 2004; 8-.R248-R250
44. Court O, Kumar A, Parrillo JE, et al: Clinical review. Myocardial depression in sepsis and septic shock. Crit Care 2002; 6:500-508
45. Tomaru Ki K, Arai M, Yokoyama T, et al: Transcriptional activation of the BNP gene by lipopolysaccharide is mediated through GATA elements in neonatal rat cardiac myocytes. J Mol Cell Cardiol 2002; 34:649-659
46. He Q, LaPointe MC: Interleukin-1beta regulation of the human brain natriuretic peptide promoter involves Ras-, Rac-, and p38 kinase-dependent pathways in cardiac myocytes. Hypertension 1999; 33:283-289
47. He Q, LaPointe MC: Interleukin-1beta regulates the human brain natriuretic peptide promoter via Ca(2+)-dependent protein kinase pathways. Hypertension 2000; 35:292-296
48. Kuwahara K, Saito Y, Harada M, et al: Involvement of cardiotrophin-1 in cardiac myocyte-nonmyocyte interactions during hypertrophy of rat cardiac myocytes in vitro. Circulation 1999; 100:1116-1124
49. Heringlake M, Heide C, Bahlmann L, et al: Effects of tilting and volume loading on plasma levels and urinary excretion of relaxin, NT-pro-ANP, and NT-pro-BNP in male volunteers. J Appl Physiol 2004; 97:173-179
50. Doyama K, Fukumoto M, Takemura G, et al: Expression and distribution of brain natriuretic peptide in human right atria. J Am Coll Cardiol 1998; 32:1832-1838
51. Hill NS, Klinger JR, Warburton RR, et al: Brain natriuretic peptide: Possible role in the modulation of hypoxic pulmonary hypertension. Am J Physiol 1994; 266: L308-L315
52. Cargill RI, Lipworth BJ: Acute effects of ANP and BNP on hypoxic pulmonary vasoconstriction in humans. Br J Clin Pharmacol 1995; 40:585-590
53. Cargill RI, Lipworth BJ: Atrial natriuretic peptide and brain natriuretic peptide in cor pulmonale. Hemodynamic and endocrine effects. Chest 1996; 110:1220-1225
54. Zhao L, Long L, Morrell NW, et al: NPR-A-deficient mice show increased susceptibility to hypoxia-induced pulmonary hypertension. Circulation 1999; 99:605-607
55. Leuchte HH, Holzapfel M, Baumgartner RA, et al: Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004; 43:764-770
56. Nagaya N, Nishikimi T, Uematsu M, et al: Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102:865-870
57. Nagaya N, Nishikimi T, Okano Y, et al: Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998; 31:202-208
58. Goetze JP, Videbaek R, Boesgaard S, et al: Pro-brain natriuretic peptide as marker of cardiovascular or pulmonary causes of dyspnea in patients with terminal parenchymal lung disease. J Heart Lung Transplant 2004; 23:80-87
59. Reynolds EW, Ellington JG, Vranicar M, et al: Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatrics 2004; 114:1297-1304
60. Book WM, Hott BJ, McConnell M: B-type natriuretic peptide levels in adults with congenital heart disease and right ventricular failure. Am J Cardiol 2005; 95:545-546
61. Ando T, Ogawa K, Yamaki K, et al: Plasma concentrations of atrial, brain, and C-type natriuretic peptides and endothelin-1 in patients with chronic respiratory diseases. Chest 1996; 110:462-468
62. Bando M, Ishii Y, Sugiyama Y, et al: Elevated plasma brain natriuretic peptide levels in chronic respiratory failure with cor pulmonale. Respir Med 1999; 93:507-514
63. Ishii J, Nomura M, Ito M, et al: Plasma concentration of brain natriuretic peptide as a biochemical marker for the evaluation of right ventricular overload and mortality in chronic respiratory disease. Clin Chim Acta 2000; 301:19-30
64. Mukerjee D, Yap LB, Holmes AM, et al: Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. Respir Med 2003; 97:1230-1236
65. Hesselstrand R, Ekman R, Eskilsson J, et al: Screening for pulmonary hypertension in systemic sclerosis: The longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001. Rheumatology 2005; 44:366-371
66. Leuchte HH, Neurohr C, Baumgartner R, et al: Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2004; 170:360-365
67. Mariano-Goulart D, Eberle MC, Boudousq V, et al: Major increase in brain natriuretic peptide indicates right ventricular systolic dysfunction in patients with heart failure. Eur J Heart Fail 2003; 5:481-488
68. Wilkins MR, Paul GA, Strange JW, et al: Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SER-APH) Study. Am J Respir Crit Care Med Epub 2005 Mar 4
69. Nagaya N, Sasaki N, Ando M, et al: Prosta-cyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension. Chest 2003; 123:338-343
70. Nagaya N, Ando M, Oya H, et al: Plasma brain natriuretic peptide as a noninvasive marker for efficacy of pulmonary thromboendarterectomy. Ann Thorac Surg 2002; 74:180-184
71. Barst RJ, McGoon M, Torbicki A, et al: Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43(12 Suppl 1):S40-S47
72. Vieillard-Baron A, Schmitt JM, Augarde R, et al: Acute cor pulmonale in acute respiratory distress syndrome submitted to protective ventilation: Incidence, clinical implications, and prognosis. Crit Care Med 2001; 29:1551-1555
73. Mitaka C, Hirata Y, Nagura T, et al: Increased plasma concentrations of brain natriuretic peptide in patients with acute lung injury. J Crit Care 1997; 12:66-71
74. Bayes-Genis A, Bellido-Casado J, Zapico E, et al: N-terminal pro-brain natriuretic peptide reflects pulmonary capillary leakage in patients with acute dyspnea. Am J Cardiol 2004; 94:669-670
75. Gerbes AL, Dagnino L, Nguyen T, et al: Transcription of brain natriuretic peptide and atrial natriuretic peptide genes in human tissues. J Clin Endocrinol Metab 1994; 78:1307-1311
76. Berman B, Spragg R, Maisel A: B-type natriuretic peptide (BNP) levels in differentiating congestive heart failure from acute respiratory distress syndrome (ARDS). Abstr. Circulation 2002; 106:83191
77. Goldhaber SZ, Visani L, De Rosa M: Acute pulmonary embolism: Clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353:1386-1389
78. Kruger S, Graf J, Merx MW, et al: Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism. Am Heart J 2004; 147:60-65
79. Kucher N, Printzen G, Goldhaber SZ: Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation 2003; 107:2545-2547
80. Kucher N, Printzen G, Doernhoefer T, et al: Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation 2003; 107:1576-1578
81. Pruszczyk P, Kostrubiec M, Bochowicz A, et al: N-terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism. Eur Respir J 2003; 22:649-653
82. ten Wolde M, Tulevski II, Mulder JW, et al: Brain natriuretic peptide as a predictor of adverse outcome in patients with pulmonary embolism. Circulation 2003; 107:2082-2084
83. Konstantinides S, Geibel A, Heusel G, et al: Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002; 347:1143-1150
84. Kreit JW: The impact of right ventricular dysfunction on the prognosis and therapy of normotensive patients with pulmonary embolism. Chest 2004; 125:1539-1545
85. Gan SC, Beaver SK, Houck PM, et al: Treatment of acute myocardial infarction and 30-day mortality among women and men. N Engl J Med 2000; 343:8-15
86. Incalzi RA, Fuso L, Serra M, et al: Exacerbated chronic obstructive pulmonary disease: A frequently unrecognized condition. J Mem Med 2002; 252:48-55
87. McCullough PA, Hollander JE, Nowak RM, et al: Uncovering heart failure in patients with a history of pulmonary disease: Rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med 2003; 10:198-204
88. Cabanes L, Richaud-Thiriez B, Fulla Y, et al: Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea. Chest 2001; 120:2047-2050
89. Lang CC, Coutie WJ, Struthers AD, et al: Elevated levels of brain natriuretic peptide in acute hypoxaemic chronic obstructive pulmonary disease. Clin Sci 1992; 83:529-533
90. Cataliotti A, Malatino LS, Jougasaki M, et al: Circulating natriuretic peptide concentrations in patients with end-stage renal disease: Role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc 2001; 76:1111-1119
91. McCullough PA, Duc P, Omland T, et al: B-type natriuretic peptide and renal function in the diagnosis of heart failure: An analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003; 41:571-579
92. Takami Y, Horio T, Iwashima Y, et al: Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF. Am J Kidney Dis 2004; 44:420-428
93. Mueller C, Laule-Kilian K, Scholer A, et al: B-type natriuretic peptide for acute dyspnea in patients with kidney disease: Insights from a randomized comparison. Kidney Int 2005; 67:278-284
94. Lee SW, Song JH, Kim GA, et al: Plasma brain natriuretic peptide concentration on assessment of hydration status in hemodialysis patient. Am J Kidney Dis 2003; 41:1257-1266
95. Wahl HG, Graf S, Renz H, et al: Elimination of the cardiac natriuretic peptides B-type natriuretic peptide (BNP) and N-terminal proBNP by hemodialysis. Clin Chem 2004; 50:1071-1074
96. Nishikimi T, Futoo Y, Tamano K, et al: Plasma brain natriuretic peptide levels in chronic hemodialysis patients: Influence of coronary artery disease. Am J Kidney Dis 2001; 37:1201-1208
97. Osajima A, Okazaki M, Kato H, et al: Clinical significance of natriuretic peptides and cyclic GMP in hemodialysis patients with coronary artery disease. Am J Nephrol 2001; 21:112-119
98. Balik M, Jabor A, Kolar M, et al: Relationship between natriuretic peptides and residual diuresis during continuous hemodiafiltration. Blood Purif 2003; 21:401-408
99. Apple FS, Murakami MM, Pearce LA, et al: Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. Clin Chem 2004; 50:2279-2285
100. Porcel JM, Vives M, Cao G, et al: Measurement of pro-brain natriuretic peptide in pleural fluid for the diagnosis of pleural effusions due to heart failure. Am J Med 2004; 116:417-420
101. Tomcsanyi J, Nagy E, Somloi M, et al: NT-brain natriuretic peptide levels in pleural fluid distinguish between pleural transudates and exudates. Eur J Heart Fail 2004; 6:753-756
102. Light RW, Macgregor MI, Luchsinger PC, et al: Pleural effusions: The diagnostic separation of transudates and exudates. Ann Intern Med 1972; 77:507-513
103. Terazawa E, Dohi S, Akamastsu S, et al: Changes in calcitonin gene-related peptide, atrial natriuretic peptide and brain natriuretic peptide in patients undergoing coronary artery bypass grafting. Anaesthesia 2003; 58:223-232
104. Hutfless R, Kazanegra R, Madani M, et al: Utility of B-type natriuretic peptide in predicting postoperative complications and outcomes in patients undergoing heart surgery. J Am Coll Cardiol 2004; 43:1873-1879
105. Cuthbertson BH, McKeown A, Croal BL, et al: Utility of B-type natriuretic peptide in predicting the level of peri- and postoperative cardiovascular support required after coronary artery bypass grafting. Crit Care Med 2005; 33:437-442
106. Kerbaul F, Collart F, Giorgi R, et al: Increased plasma levels of pro-brain natriuretic peptide in patients with cardiovascular complications following off-pump coronary artery surgery. Intensive Care Med 2004; 30:1799-1806
107. Terasako K: Perioperative plasma concentrations of atrial and brain natriuretic peptides in patients undergoing hip arthroplasty. Anaesth Intensive Care 2002; 30:588-590
108. Berendes E, Schmidt C, Van Aken H, et al: A-type and B-type natriuretic peptides in cardiac surgical procedures. Anesth Analg 2004; 98:11-19
109. Tayama K, Takamori S, Mitsuoka M, et al: Natriuretic peptides after pulmonary resection. Ann Thorac Surg 2002; 73:1582-1586
110. Sodian R, Loebe M, Schmitt C, et al: Decreased plasma concentration of brain natriuretic peptide as a potential indicator of cardiac recovery in patients supported by mechanical circulatory assist systems. J Am Coll Cardiol 2001; 38:1942-1949
111. Henriksen JH, Gotze JP, Fuglsang S, et al: Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: Relation to cardiovascular dysfunction and severity of disease. Gut 2003; 52:1511-1517
112. Iwao T, Oho K, Nakano R, et al: High plasma cardiac natriuretic peptides associated with enhanced cyclic guanosine monophosphate production in preascitic cirrhosis. J Hepatol 2000; 32:426-433
113. Espiner EA, Leikis R, Ferch RD, et al: The neuro-cardio-endocrine response to acute subarachnoid haemorrhage. Clin Endocrinol 2002; 56:629-635
114. Berendes E, Walter M, Cullen P, et al: Secretion of brain natriuretic peptide in patients with aneurysmal subarachnoid haemorrhage. Lancet 1997; 349:245-249
115. Fukui S, Katoh H, Tsuzuki N, et al: Focal brain edema and natriuretic peptides in patients with subarachnoid hemorrhage. J Clin Neurosci 2004; 11:507-511
116. Sviri GE, Feinsod M, Soustiel JF: Brain natriuretic peptide and cerebral vasospasm in subarachnoid hemorrhage. Clinical and TCD correlations. Stroke 2000; 31:118-122
117. McGirt MJ, Blessing R, Nimjee SM, et al: Correlation of serum brain natriuretic peptide with hyponatremia and delayed ischemic neurological deficits after subarachnoid hemorrhage. Neurosurgery 2004; 54:1369-1373
118. Makikallio AM, Makikallio TH, Korpelainen JT, et al: Natriuretic peptides and mortality after stroke. Stroke 2005; 36:1016-1020
119. Daugaard G, Lassen U, Bie P, et al: Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail 2005; 7:87-93
120. Ohsaki Y, Gross AJ, Le PT, et al: Human small cell lung cancer cells produce brain natriuretic peptide. Oncology 1999; 56:155-159
121. Liang F, Webb P, Marimuthu A, et al: Triiodothyronine increases brain natriuretic peptide (BNP) gene transcription and amplifies endothelin-dependent BNP gene transcription and hypertrophy in neonatal rat ventricular myocytes. J Biol Chem 2003; 278:15073-15083
122. Schultz M, Faber J, Kistorp C, et al: N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) in different thyroid function states. Clin Endocrinol 2004; 60:54-59
123. McNairy M, Gardetto N, Clopton P, et al: Stability of B-type natriuretic peptide levels during exercise in patients with congestive heart failure: Implications for outpatient monitoring with B-type natriuretic peptide. Am Heart J 2002; 143:406-411
124. Loke I, Squire IB, Davies JE, et al: Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate. Eur J Heart Fail 2003; 5:599-606
125. Knudsen CW, Vik-Mo H, Omland T: Blood haemoglobin is an independent predictor of B-type natriuretic peptide levels. Clin Sci Epub 2005 Mar 8
126. Brotman DJ, Girod JP, Garcia MJ, et al: Effects of short-term glucocorticoids on cardiovascular biomarkers. J Clin Endocrinol Metab Epub 2005 Mar 15
127. Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al: Plasma brain natriuretic peptide concentration: Impact of age and gender. J Am Coll Cardiol 2002; 40:976-982
128. Wang TJ, Larson MG, Levy D, et al: Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002; 90:254-258
129. Raizada V, Thakore K, Luo W, et al: Cardiac chamber-specific alterations of ANP and BNP expression with advancing age and with systemic hypertension. Mol Cell Biochem 2001; 216:137-140
130. Sayama H, Nakamura Y, Saito N, et al: Why is the concentration of plasma brain natriuretic peptide in elderly inpatients greater than normal? Coron Artery Dis 1999; 10:537-540
131. Ray P, Arthaud M, Lefort Y, et al: Usefulness of B-type natriuretic peptide in elderly patients with acute dyspnea. Intensive Care Med 2004; 30:2230 -2236
132. Maisel AS, Clopton P, Krishnaswamy P, et al: Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: Results from the Breathing Not Properly (BNP) Multinational Study. Am Heart J 2004; 147:1078-1084
133. Yano Y, Katsuki A, Gabazza EC, et al: Plasma brain natriuretic peptide levels in normotensive noninsulin-dependent diabetic patients with microalbuminuria. J Clin Endocrinol Metab 1999; 84:2353-2356
134. Magnusson M, Melander O, Israelsson B, et al: Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular disease. Diabetes Care 2004; 27:1929-1935
135. Wang TJ, Larson MG, Levy D, et al: Impact of obesity on plasma natriuretic peptide levels. Circulation 2004; 109:594-600
136. Mehra MR, Uber PA, Park MH, et al: Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 2004; 43:1590-1595
137. McCord J, Mundy BJ, Hudson MP, et al: Relationship between obesity and B-type natriuretic peptide levels. Arch Mem Med 2004; 164:2247-2252
138. Kita H, Ohi M, Chin K, et al: The nocturnal secretion of cardiac natriuretic peptides during obstructive sleep apnoea and its response to therapy with nasal continuous positive airway pressure. J Sleep Res 1998; 7:199-207
139. Moller DS, Lind P, Strunge B, et al: Abnormal vasoactive hormones and 24-hour blood pressure in obstructive sleep apnea. Am J Hypertens 2003; 16:274-280
140. Svatikova A, Shamsuzzaman AS, Wolk R, et al: Plasma brain natriuretic peptide in obstructive sleep apnea. Am J Cardiol 2004; 94:529-532
141. Yoshimura M, Yasue H, Okumura K, et al: Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993; 87:464-469
142. Richards AM, Crozier IG, Yandle TG, et al: Brain natriuretic factor: Regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br Heart J 1993; 69:414 -417
143. Maeda K, Tsutamoto T, Wada A, et al: Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998; 135:825-832
144. Kazanegra R, Cheng V, Garcia A, et al: A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: A pilot study. J Card Fail 2001; 7:21-29
145. Parsonage WA, Galbraith AJ, Koerbin GL, et al: Value of B-type natriuretic peptide for identifying significantly elevated pulmonary artery wedge pressure in patients treated for established chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2005; 95:883-885
146. Dokainish H, Zoghbi WA, Lakkis NM, et al: Optimal noninvasive assessment of left ventricular filling pressures: A comparison of tissue Doppler echocardiography and B-type natriuretic peptide in patients with pulmonary artery catheters. Circulation 2004; 109:2432-2439